Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Bayer to Increase Sales of Oncology Products to \50 Bil.
August 11, 2008
- MEDICAL DEVICE NEWS IN BRIEF
August 11, 2008
- Gov't Announces Five Plans for Assurance
August 11, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF)
August 11, 2008
- \220 Bil. Cut in Social Security Spending Approved by Cabinet
August 11, 2008
- Survival Improved by Treatment of Post-stroke Depression
August 11, 2008
- Taxotere to Be Approved for Prostate Cancer
August 11, 2008
- Vaccines Effective in Preventing Bacterial Meningitis: Wyeth
August 11, 2008
- GSK's Lamotrigine Recommended for Approval
August 11, 2008
- Long-term Lipovas Administration Useful: Banyu
August 11, 2008
- BUSINESS NEWS IN BRIEF
August 11, 2008
- Isentress Key Drug in HIV Treatment: Banyu
August 11, 2008
- Tokushukai Committed to Settling Prices by End of September
August 11, 2008
- R&D NEWS IN BRIEF
August 11, 2008
- MSNW Supports Rational Drug Pricing
August 11, 2008
- GENERICS NEWS IN BRIEF
August 11, 2008
- JPMA Members Improving Distribution Business Practices: Mr Negi
August 11, 2008
- JRCS Considers Joint Purchase of Generics
August 11, 2008
- Price Settlement Rate Remains at 18% as of June 30: NPhA
August 11, 2008
- Gov't Plans to Create 20 "Super Tokku"
August 11, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…